What is new within staging of care for people with dementia? The IDEAL schedule and other recent work

Semrau, Maya; Sartorius, Norman

doi:10.1097/yco.0000000000000508

Cited by 2 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the aging population and a growing incidence of dementia, acknowledgement of dementia as a chronic and irreversible condition is becoming more prevalent 1 . Dementia is generally considered severe when there is evidence of severe cognitive and functional impairment, often with significant behavioral symptoms and dependence for activities of daily living 2 . Cut‐off scores for severe dementia have been variously proposed on validated cognitive measures to assist with disease staging (Table 1).…”

Section: Introductionmentioning

confidence: 99%

“…1 Dementia is generally considered severe when there is evidence of severe cognitive and functional impairment, often with significant behavioral symptoms and dependence for activities of daily living. 2 Cut-off scores for severe dementia have been variously proposed on validated cognitive measures to assist with disease staging (Table 1). At the late stage of disease, profound cognitive and functional disability is often accompanied by multiple comorbidities prompting additional medical management.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Tools for deprescribing in severe dementia: A scoping review

Wang

Smith

et al. 2023

Int J Geriat Psychiatry

View full text Add to dashboard Cite

Objectives: Identification of inappropriate medications in people living with severe dementia is a complex task which has the potential to reduce avoidable adverse events and increase quality of life. This scoping review (i) identifies published tools intended to aid deprescribing in people living with severe dementia and (ii) describes evaluations of their usefulness in clinical practice. Methods: A scoping review was undertaken, with Medline, Medline in Process, EMBASE, Cochrane Library, CINAHL, Scopus and Web of Science databases, from inception to April 2023, identifying tools for deprescribing in severe dementia. A tool was considered as any resource for deprescribing, including clinical study, scientific publication, health guideline, website, algorithm, model or framework. Two reviewers assessed the eligibility of articles through abstract and full text review. Data extracted from included studies were summarized through narrative synthesis. Results: Twelve studies were identified from 18,633 articles screened. Tools were categorized into three groups: deprescribing interventions (n = 2), consensus-based deprescribing criteria (n = 5), and medication-specific recommendations (n = 5). Six studies developed tools using expert opinion and ten tools were tested in people living with severe dementia. Only one of the four studies that evaluated patient outcomes (cognitive change and adverse events) identified clear clinical benefit from medication withdrawal. Conclusions: Clinical application of current deprescribing tools is limited due to the lack of evidence-based research on the clinical effects of individual medication deprescribing in people with severe dementia. Further research on patient outcomes, including cognitive change and adverse events, will help clarify the role of these tools in clinical care.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%